Repeat Therapeutics

Repeat Therapeutics is a biotechnology company focused on developing novel small molecule therapies for repeat expansion diseases. Founded by industry veteran Peter Lansbury, the company leverages a proprietary platform to target the underlying genetic repeats responsible for neurodegenerative and neuromuscular disorders. Their primary focus includes conditions such as Huntington's disease, ALS, and myotonic dystrophy. By specifically modulating the expansion or expression of these repetitive sequences, Repeat Therapeutics aims to provide disease-modifying treatments for patients with limited options. The company is currently in the pre-clinical stage, advancing a pipeline of discovery-stage programs.